Top Markets
#1 MowCat MowCat +775.59%
#2 龙虾 (Lobster) 龙虾 (Lobster) +81.18%
#3 Akedo Akedo +43.02%
#4 Magma Finance Magma Finance +42.54%
#5 SIXSEVEN SIXSEVEN +28.89%
#6 MarsCoin MarsCoin +27.75%
#7 DeXe DeXe +27.23%
#8 Cortex Cortex +25.74%
#9 Staked ZIG Staked ZIG +16.36%
#10 Zignaly Zignaly +16.25%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Seaport Therapeutics, Inc. Common Stock Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock

SPTX
Rangering i aksjer #8294
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise... Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Aksjekurs
$24.37
Markedsverdi
$1.30B
Endring (1 dag)
-7.16%
Endring (1 år)
-
Land
US
Handel Seaport Therapeutics, Inc. Common Stock (SPTX)

Kategori

Healthcare
P/E-forhold for Seaport Therapeutics, Inc. Common Stock (SPTX)
P/E-forhold per 2026 TTM: 0
Ifølge Seaport Therapeutics, Inc. Common Stock sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Seaport Therapeutics, Inc. Common Stock fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.